The DnaJ Homolog Subfamily C Member 15 pipeline drugs market research report outlays comprehensive information on the DnaJ Homolog Subfamily C Member 15 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the DnaJ Homolog Subfamily C Member 15 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Gastrointestinal, Oncology, Genito Urinary System, and Genetic Disorders which include the indications Metabolic Dysfunction-Associated Steatohepatitis (MASH), Hepatic Injury, Breast Cancer, Acute Renal Failure (ARF) (Acute Kidney Injury), and Polycystic Kidney Disease. It also reviews key players involved in DnaJ Homolog Subfamily C Member 15 targeted therapeutics development with respective active and dormant or discontinued products.
The DnaJ Homolog Subfamily C Member 15 pipeline targets constitutes close to five molecules. Out of which, approximately five molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Preclinical, and Discovery stages are 3, and 2 respectively.
DnaJ Homolog Subfamily C Member 15 overview
DNAJ Homolog Subfamily C Member 15 (DNAJC15) belongs to the DNAJ/HSP40 protein family, which plays a crucial role in protein folding, assembly, and degradation processes within the cell. DNAJC15, specifically, is involved in endoplasmic reticulum (ER)-associated protein degradation (ERAD), a cellular pathway responsible for disposing of misfolded proteins from the ER. As a co-chaperone, DNAJC15 collaborates with molecular chaperones to facilitate the recognition and targeting of misfolded proteins for degradation. It interacts with E3 ubiquitin ligases and participates in the ubiquitin-proteasome system, marking misfolded proteins for degradation. DNAJC15’s role in ERAD contributes to the maintenance of cellular proteostasis by preventing the accumulation of aberrant proteins that could compromise cellular function. Dysregulation of ERAD has been implicated in various diseases, including neurodegenerative disorders and certain cancers.
For a complete picture of DnaJ Homolog Subfamily C Member 15’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
